Financial Relationships Between Pharmaceutical Companies and Rheumatologists in Japan Between 2016 and 2019

Article Medicine, General & Internal

Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology

Ali Duarte-Garcia et al.

Summary: Payments from pharmaceutical companies to rheumatologists are associated with increased probability of prescribing and Medicare spending.

MAYO CLINIC PROCEEDINGS (2022)

Add to Collection

Article Medicine, General & Internal

Sunshine on KOLs: assessment of the nature, extent and evolution of financial ties between the leaders of professional medical associations and the pharmaceutical industry in France from 2014 to 2019: a retrospective study

Marie Clinckemaillie et al.

Summary: This study aims to investigate the financial relationships between key opinion leader (KOL) or non-KOL physicians and pharmaceutical and device companies in France. The results show that KOLs have extensive financial ties with the industry, receiving high-value gifts, remunerations, and contractual agreements.

BMJ OPEN (2022)

Add to Collection

Article Public, Environmental & Occupational Health

How Do Institutional Conflicts of Interest Between Pharmaceutical Companies and the Healthcare Sector Become Corrupt? A Case Study of Scholarship Donations Between Department of Clinical Anesthesiology, Mie University, and Ono Pharmaceutical in Japan

Akihiko Ozaki et al.

Summary: Scholarship donations, a unique donation scheme in Japan, can encourage educational and academic activities related to new drug development in healthcare organizations, but they can also be used as bribes by pharmaceutical companies. An analysis of a recent scandal involving scholarship donations sheds light on the issues of ICOIs in the Japanese healthcare sector and suggests potential institutional remedies to address corrupt behavior.

FRONTIERS IN PUBLIC HEALTH (2022)

Add to Collection

Letter Peripheral Vascular Disease

The Diovan scandal in Japan; don't let bygones be bygones

Nanami Murata et al.

JOURNAL OF HUMAN HYPERTENSION (2022)

Add to Collection

Letter Oncology

Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019

Eiji Kusumi et al.

BLOOD CANCER JOURNAL (2022)

Add to Collection

Article Environmental Sciences

Awareness and Perceptions among Members of a Japanese Cancer Patient Advocacy Group Concerning the Financial Relationships between the Pharmaceutical Industry and Physicians

Anju Murayama et al.

Summary: This study assessed the awareness, influence on physician trustworthiness, and perception of financial conflicts of interest (FCOI) between pharmaceutical companies and healthcare domains among the Japanese cancer patient advocacy group members. Most respondents were aware of physician-Pharma interactions, considered them influential on clinical practice, and supported further regulation to protect patient-centered care.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2022)

Add to Collection

Article Environmental Sciences

Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019

Anju Murayama et al.

Summary: This study retrospectively assessed the financial relationships between board-certified infectious disease specialists in Japan and pharmaceutical companies. The results showed substantial financial ties between these specialists and the companies, with higher-ranked specialists having stronger financial connections.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2022)

Add to Collection

Review Medicine, General & Internal

Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing? A Systematic Review

Aaron P. Mitchell et al.

Summary: The study found that financial payments from the drug industry to U.S. physicians are associated with physician prescribing practices, including increased prescribing of the paying company's drug, increased prescribing costs, and increased prescribing of branded drugs.

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

Article Rheumatology

Industry Payments to Practicing US Rheumatologists, 2014-2019

Michael S. Putman et al.

Summary: This study investigated the nature, quantity, and geographic distribution of payments from the pharmaceutical industry to US rheumatologists. Results showed that the majority of rheumatologists received less than $5,000, while a small number received over $100,000 each, accounting for a large portion of the total payments. The value of industry payments increased over time, and male rheumatologists received significantly higher payments than female rheumatologists.

ARTHRITIS & RHEUMATOLOGY (2021)

Add to Collection

Article Rheumatology